Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring |
| |
| Authors: | Xi-De Wang Karen Reeves Feng R Luo Li-An Xu Francis Lee Edwin Clark Fei Huang |
| |
| Affiliation: | (1) Pharmaceutical Research Institute, Bristol-Myers Squibb, Princeton, 08543, New Jersey, USA |
| |
| Abstract: | Background Dasatinib is a potent, multi-targeted kinase inhibitor that was recently approved for treatment of chronic myelogenous leukemia
resistant to imatinib. To aid the clinical development of dasatinib in prostate cancer, we utilized preclinical models to
identify potential molecular markers for patient stratification and efficacy monitoring. |
| |
| Keywords: | |
| 本文献已被 PubMed SpringerLink 等数据库收录！ |
|
